Has Michael Sokol, MD received payments from drug or device companies?

Yes. Drug and device makers reported $227,388 in general payments to Michael Sokol, MD across 1,460 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Sokol, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Sokol, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Sokol, MD

Endocrinology, Diabetes & Metabolism · Overland Park, KSNPI 1235163676

Payments from drug & device makers

$227,388in general payments, 2019–2025

Across 1,460 payments — averaging $155.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$86K
Novo Nordisk$42K
Johnson & Johnson$21K
Abbott$18K
AstraZeneca$14K
Mannkind Corporation$11K
plus $36K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	193	$85,783
Novo Nordisk	224	$41,533
Johnson & Johnson	43	$20,727
Abbott	86	$17,712
AstraZeneca(2 entities)	77	$13,526
Mannkind Corporation	79	$11,390
Nestle Healthcare Nutrition Inc.	13	$9,535
Bayer	22	$5,716
Clarus Therapeutics Inc.	8	$3,952
Amgen(2 entities)	96	$3,498
AbbVie(2 entities)	100	$1,575
Aimmune Therapeutics, Inc.	2	$1,377
Sanofi-aventis U.S. LLC	49	$1,018
Xeris Pharmaceuticals, Inc.	59	$1,015
Pfizer	63	$782
Corcept Therapeutics	22	$680
Chiesi USA, Inc.	3	$642
Radius Health, Inc.	23	$596
Amarin Pharma, Inc.	27	$591
Boehringer Ingelheim	21	$410
Dexcom, Inc.	11	$340
Esperion Therapeutics, Inc.	13	$311
Tandem Diabetes Care, Inc.	5	$310
Amneal Pharmaceuticals LLC	17	$290
Antares Pharma, Inc.	16	$260
Merck	18	$238
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	13	$231
Eisai Inc.	12	$203
Medtronic(2 entities)	7	$196
BETA Bionics, Inc.	2	$182
Currax Pharmaceuticals LLC	16	$173
Astellas Pharma US Inc	9	$169
Neurocrine Biosciences, Inc.	3	$155
Kyowa Kirin, Inc.	5	$122
Pharmacosmos Therapeutics Inc.	1	$114
Axsome Therapeutics, Inc.	2	$110
Insulet Corporation	5	$96
Kowa Pharmaceuticals America, Inc.	7	$95
Senseonics, Incorporated	2	$91
Daiichi Sankyo Inc.	4	$88
IBSA Pharma Inc.	5	$88
GSK	6	$87
Recordati_rare_diseases_inc.	4	$80
Exact Sciences	5	$78
Ultragenyx Pharmaceutical Inc.	4	$73
Alnylam Pharmaceuticals Inc.	4	$73
Sanofi	1	$72
Biohaven Pharmaceutical Holding Company Ltd.	4	$70
Protega Pharmaceutials Inc	3	$67
Idorsia Pharmaceuticals US Inc	3	$63
Biohaven Pharmaceuticals, Inc.	3	$57
Takeda Pharmaceuticals U.S.A., Inc.	3	$51
Nevro Corp.	2	$48
Ascendis Pharma Endocrinology Inc	2	$47
Biogen	2	$47
Novartis	3	$42
Lifescan, Inc.	2	$37
Sandoz	1	$33
Amryt Pharma Holdings Ltd	2	$33
Ipsen Biopharmaceuticals, Inc	1	$30

How this compares

$227,388 in reported general payments places this provider in the 90th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

See all endocrinology, diabetes & metabolism providers in Kansas →

Medicare billing

Part B allowed, 2024

$564,109

Medicare patients

741

Services billed

35,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Overland Park

Sajeev MenonOverland Park$26K
M Yaser MounlaOverland Park$9K
Mini AbrahamOverland Park$550
Marie GriffinOverland Park$303
Jeffrey KallsenOverland Park$80
Alan WynneTopeka$6.9M
Susan BrianTopeka$2.8M
Dany ZayourWichita$744K
Andrew GreenShawnee Mission$322K
Rami MortadaWichita$105K

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →